Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology products for pharmaceutical, life-science and other applications.

Starpharma's lead product is VivaGel™, a gel-based formulation of a nano-pharmaceutical that is being developed as a vaginal microbicide to protect women from the sexually transmitted infections, HIV and genital herpes.

VivaGel™ has been successfully tested in a Phase I clinical trial, with new trials currently underway in Australia, the United States and Kenya. VivaGel™ has been granted Fast Track status by the US Food and Drug Administration (FDA) which will accelerate the clinical and regulatory process. In addition, VivaGel™ has been awarded US$20.3 million by the NIH to accelerate its development for HIV. The NIH has provided additional funding support to develop VivaGel™ against genital herpes.

In October 2006 Starpharma acquired US-based Dendritic Nanotechnologies Inc (DNT) expanding the company's potential products to include drug delivery and industrial specialty chemical appliances. Many of these applications have near-term cash-flow opportunities.